At necropsy the small-bowel mucosa was congested and haemorrhagic with small ulcerations. Because of autolysis and degeneration of mucosa, small-bowel CMV could not be confirmed or excluded. There were multiple infarcts in the kidneys and spleen and the mitral valve was calcified with multiple small thrombotic vegetations on the anterior leaf. It was postulated that small-bowel, renal and splenic infarcts had resulted from embolization of these vegetations. COMMENT Though seldom described in patients with no previous immunodeficiency state, CMV colitis is known to be associated with inflammatory bowel disease24. Most commonly it occurs in patients with impaired T cell function-for example, patients with AIDS or patients on cytotoxic chemotherapy. In the case described here, lifethreatening haemorrhage secondary to CMV colitis occurred after 4 weeks of intensive care in a critically ill patient with multiorgan failure due to serious bacterial sepsis. She had no history of inflammatory bowel disease or of cytotoxic or other immunosuppressive therapy, and was HIV-antibody negative. It therefore seems likely that CMV infection was reactivated as a result of severe bacterial sepsis. Although mild (possibly symptomless) reactivated infection may occur within four days of the onset of severe sepsis2, overt disease usually takes upwards of two weeks to develop in patients on immunosuppressive therapy3. CMV colitis should be considered in the differential diagnosis of rectal bleeding in critically ill patients irrespective of previous immune status.
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Respiratory syncytial virus (RSV) is the principal cause of bronchiolitis in infancy. In most cases the bronchiolitis is mild and self-limiting but in some the disease is severe and even fatal. In such severely affected infants, nebulized ribavirin is commonly tried. We have treated an infant successfully with intravenous ribavirin.
CASE HISTORY
A nine-week-old boy weighing 2.76 kg was brought to hospital with a two-day history of cough, lethargy and poor feeding. He had been born at 28 weeks and ventilated, but had no chronic lung disease. From the onset of his illness he rapidly worsened and on arrival he was shocked and hypothermic. After initial resuscitation he developed increasing respiratory distress for which he was ventilated. White cell count on admission was 3 x 109/L, 72% lymphocytes. A chest radiograph showed bilateral pulmonary infiltrates; blood and urine bacterial cultures were negative; nasopharyngeal aspirates were positive by enzyme-linked immunosorbent assay for RSV antigens. Viral cultures were not performed. Attempts at treatment with nebulized ribavirin were abandoned because of unacceptable increases in ventilatory pressures. He was treated additionally with broad spectrum antibiotics and inotropic agents. By day 7 he was weaned off inotropes but remained difficult to ventilate. A five-day course of steroids, between days 8 and 13, was tried with no improvement. By day 17 he still required ventilatory support (pressure 25/3, rate 30, oxygen concentration 60%), radiographs showed further extension of infiltrates, and he remained RSV positive. In view of his worsening RSV pneumonia he was started on intravenous ribavirin (loading dose 20 mg/kg/ day, maintenance 15 mg/kg/day for 7 days). He rapidly improved, became RSV negative within 48 hours and was weaned to minimal ventilatory support by day 20. Figure 1 illustrates the improvement in ventilatory status. There were no evident side-effects from the ribavirin. Repeat chest radiograph showed resolution of the pneumonia and he was extubated on day 28.
COMMENT
Major epidemics of bronchiolitis occur every winter, and more than half of all susceptible infants are affected. In neonates and in infants with underlying cardiac and respiratory disease, fatal RSV pneumonia has been described. Ribavirin, a nucleoside antagonist, is the only antiviral agent effective against RSV. Small-particle aerosolized (nebulized) ribavirin has been widely used and studied but its effectiveness remains controversial. According to early reports this treatment substantially lessened the severity of illness1, especially in the initial phase in infants with underlying bronchopulmonary dysplasia and cardiac dis-ease2. When ventilated children showed a reduction in oxygen requirements and duration of ventilation with nebulized ribavirin, this treatment was recommended in bronchiolitis3. However, in a meta-analysis of the published work, neither the reduction in mortality nor the slowing of respiratory deterioration was statistically significant4. This review highlighted concerns about potential teratogenic effects of ribavirin, the difficulty of administering it through ventilators, and its very high cost.
Systemic or intravenous ribavirin has been used in immunocompromised patients with severe adenoviral infections and hepatitis C, and there is anecdotal evidence of its efficacy5'6. Intravenous ribavirin has lately been tried in RSV pneumonia in immunocompromised adults without apparent benefit7. The safety of systemic ribavirin over long periods has been well documented in adults and children with acquired immunodeficiency syndrome8 9.
The rapidity with which our patient improved and became RSV-negative after treatment with intravenous ribavirin suggests that ribavirin was effective here. Further studies are needed to determine the efficacy of this agent.
